Scarica l'app Stockscreener
11.13
0.23%
0.025
Pre-mercato:
11.13
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TNDM Giù?
Forum
Previsione
Frazionamento azionario
Tandem Diabetes Care Inc Borsa (TNDM) Ultime notizie
FDA clearances: Imris, Daxor Corp., Tandem Diabetes Care - Modern Healthcare
Securities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - The Globe and Mail
Software correction coming for faulty insulin pumps - Cleveland.com
Diabetes Warning Issued Over Insulin Pump Error - Newsweek
Tandem Diabetes upgraded at Citi on risk-reward setup - MSN
5 Insightful Analyst Questions From Tandem Diabetes’s Q2 Earnings Call - Yahoo Finance
Published on: 2025-08-13 16:11:40 - 선데이타임즈
Tandem Diabetes Care: Navigating Volatility and Innovation in a Polarized Market - AInvest
Tandem Diabetes' Recent Surge: Is This the Start of a Long-Term Rally or a Short-Lived Rebound? - AInvest
Tandem Diabetes Care Shares Rise After Upgrade From Citigroup - MarketScreener
Tandem Diabetes upgraded to Neutral by Citi, citing shift in risk-reward setup - AInvest
Tandem Diabetes stock upgraded at Citi (TNDM:NASDAQ) - Seeking Alpha
Tandem Diabetes at Canaccord Conference: Strategic Shifts and Market Focus - Investing.com Canada
Tandem Diabetes, iRhythm, agilon health, Fortrea, and 10x Genomics Shares Skyrocket and Plummet, What You Need To Know - TradingView
Tandem Diabetes Care Stock (TNDM) Opinions on Q2 2025 Earnings Miss - Quiver Quantitative
Citigroup Upgrades Tandem Diabetes Care to Neutral From Sell, Adjusts Price Target to $10.35 From $10 - MarketScreener
Citi Upgrades Tandem Diabetes Care to Neutral, Raises PT to $10.35 - AInvest
TNDM Q2 Deep Dive: Margin Pressures and Strategic Shifts Offset Sales Growth - ca.finance.yahoo.com
Insider Buying: John Sheridan Acquires Shares of Tandem Diabetes Care Inc (TNDM) - GuruFocus
CFRA Maintains Hold Rating on Tandem Diabetes Care with $22 Price Target - AInvest
Tandem Diabetes Downgraded to Hold by Lake Street Amid Valuation Concerns - AInvest
Tandem Diabetes Care's 2025 Q2 Earnings Call: Unpacking Contradictions in CMS Proposals, Pharmacy Strategies, and Renewal Growth - AInvest
CFRA slashes Tandem Diabetes Care stock price target on GLP-1 risks - Investing.com Canada
Tandem Diabetes Care: Pioneering the Future of Diabetes Management and a High-Conviction Growth Play in 2025 - AInvest
Tandem Diabetes Care Inc. Pipeline Analysis Report 2025: A Comprehensive Guide to the Company's Product Pipeline and Developmental Products - AInvest
Top 3 Health Care Stocks That Are Preparing To Pump This Month - Benzinga
TNDM Stock Falls on Q2 Earnings Miss, Revenues Beat, Gross Margin Up - TradingView
Tandem Diabetes Care Inc. Forms Bullish Flag — Upside AheadScalable Portfolio Growth Suggestions Released - metal.it
Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say - MSN
Tandem Diabetes projects $1B sales for 2025 as international growth, pharmacy channel, and product innovation drive outlook - MSN
Tandem Diabetes Care: Earnings Miss Confirms Bear CaseDowngrade To Sell (NASDAQ:TNDM) - Seeking Alpha
Insulin pump makers Tandem and Insulet post contrasting Q2 results - MSN
What does recent volatility data suggest for Tandem Diabetes Care Inc.Technical Analysis of Growth Stock Opportunities - Newser
Medtech Executives Monitor CMS Payment Proposal for Diabetes Technology - AInvest
How to build a custom watchlist for Tandem Diabetes Care Inc.Buy Zone Strategy with Pattern Recognition - Newser
Will Tandem Diabetes Care Inc. outperform the marketSmart Trend Analysis With Buy Point Cues - Newser
Chart based exit strategy for Tandem Diabetes Care Inc.Free Trade Ready Stock Watch for Short Term - Newser
How high can Tandem Diabetes Care Inc. stock goReal Time Screener for Growth Trades - Newser
Tandem Diabetes Care Inc. stock retracement – recovery analysisSafe Momentum Strategy With Trend Analysis - Newser
Tandem downgraded to Neutral at Piper Sandler on softer outlook - MSN
Tandem Diabetes Care Inc.’s volatility index tracking explainedWatchlist Summary for Active Day Traders - Newser
Tandem Diabetes Care’s Earnings Call Highlights Growth and Challenges - The Globe and Mail
Tandem Diabetes Care issues voluntary correction for insulin pumps - Medical Buyer
Tandem Diabetes Care shares rise 4.31% intraday after UBS adjusts price target to $17. - AInvest
Tandem, Insulet monitoring CMS payment proposal for diabetes tech - MedTech Dive
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q2 2025 Earnings Call Transcript - Insider Monkey
Positive Outlook for Tandem Diabetes Care: Buy Rating Reaffirmed Amid Growth Catalysts and Strategic Opportunities - TipRanks
Insulet Peer Tandem Diabetes Underwhelming Earnings, Dull Outlook Drags Stock - AOL.com
Tandem Diabetes Care Gains FDA Clearance for SteadiSet - TipRanks
Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Beats Revenue Estimates - MSN
Tandem Diabetes Care (TNDM.O) Sees Sharp Intraday Decline: What’s Behind the Move? - AInvest
Tandem Diabetes Care issues voluntary device correction for certain insulin pumps - Reuters
Tandem insulin pump malfunction linked to 59 injuries - MedTech Dive
Why Is Insulet Peer Tandem Diabetes Stock Trading Lower TodayTandem Diabetes Care (NASDAQ:TNDM) - Benzinga
Tandem Diabetes' Stalled Momentum: Is the Market Overestimating Long-Term Resilience? - AInvest
TNDM.O Crashes 24.5%: What’s Behind the Sharp Drop? - AInvest
Tandem Diabetes Care price target lowered to $20 at TD Cowen on US sales concerns - Investing.com Canada
Tandem Diabetes announces medical device correction for t:slim X2 insulin pumps - TipRanks
TNDM.O Plummets 25%—What’s Behind the Sharp Move? - AInvest
UBS Adjusts Price Target on Tandem Diabetes Care to $17 From $20, Maintains Neutral Rating - MarketScreener
Earnings call transcript: Tandem Diabetes Care Q2 2025 misses EPS expectations - Investing.com Nigeria
Tandem Diabetes Care hits 7-year low on issuing voluntary device correction for certain insulin pumps - TradingView
Tandem Diabetes Plunges 21.2%: Can a Speaker Glitch Spell the End of a Diabetes Tech Giant? - AInvest
0.31%
1.36%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):